6. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology. 2004;50(5):722-733.
7. Roldán-Marín R, Toussaint-Caire S. Imiquimod 5% as adjuvant therapy for incompletely excised infiltrative nodular basal cell carcinoma and dermoscopy to monitor treatment response. Dermatology and Therapy. 2015;5(4):265-272.
8. McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (SBCC) predicts imiquimod efficacy: A proposal for a thickness-based definition of SBCC. British Journal of Dermatology. 2013;169(3):549-554.
9. Roozeboom MH, Arits AHHM, Nelemans PJ, et al. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. British Journal of Dermatology. 2012;167(4):733-756.
10. Sharquie KE, Noaimi AA. Basal cell carcinoma: topical therapy versus surgical treatment. Journal of the Saudi Society of Dermatology & Dermatologic Surgery. 2012;16(2):41-51.
11. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. Journal of the American Academy of Dermatology. 2018;78(3):540-559.
12. van Delft LCJ, Nelemans PJ, Kessels JPHM, et al. Long-term efficacy of photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus conventional two-stage topical methyl aminolevulinate for superficial basal-cell carcinoma. Dermatology. 2022;238(6):1044-1049.
13. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. International Journal of Dermatology. 2006;45(5):489-498.
14. Habashy S, Jafri A, Osman HO, et al. Hedgehog pathway inhibitors: Clinical implications and resistance in the treatment of basal cell carcinoma. Cureus. 2021;13(3):13859.
15. Nguyen NM, Cho J. Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance. International Journal of Molecular Sciences. 2022;23(3):1733.
16. Gambini D, Passoni E, Nazzaro G, et al. Basal cell carcinoma and hedgehog pathway inhibitors: Focus on immune response. Frontiers in Medicine. 2022;9.
17. Yin VT, Sniegowski M, Esmaeli B. Indications and limitations of vismodegib for basal cell carcinoma. JAMA Ophthalmology. 2014;132(7):905-906.
18. Cozzani R, Aguila R, Carrizo M, et al. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina. International Journal of Dermatology. 2020;59(5):627-632.
19. ClinicalTrials.gov. Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin SynDrome Patients – Full Text View. [cited 2023 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02762084.
20. ClinicalTrials.gov. Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas – Full Text View. [cited 2023 Mar 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02828111.
21. Villani A, Potestio L, Fabbrocini G, et al. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Advances in Therapy. 2022;39(3):1164-1178.
22. Verkouteren BJA, Sinx KAE, Reinders MGHC, et al. Update on hedgehog pathway inhibitor therapy for patients with basal cell naevus syndrome or high-frequency basal cell carcinoma. Acta Dermato-Venereologica. 2022;102:980.
23. Zeng L, Gowda BH, Ahmed MG, et al. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Molecular Cancer. 2023;22(1).
24. Souto EB, Macedo AS, Dias-Ferreira J, et al. Elastic and ultradeformable liposomes for transdermal delivery of active pharmaceutical ingredients (apis). International Journal of Molecular Sciences. 2021;22(18):9743.
25. Zielińska A, Szalata M, Gorczyński A, et al. Cancer nanopharmaceuticals: Physicochemical characterization and in vitro/in vivo applications. Cancers. 2021;13(8):1896.
26. Calienni MN, Febres-Molina C, Llovera RE, et al. Nanoformulation for potential topical delivery of Vismodegib in skin cancer treatment. International Journal of Pharmaceutics. 2019;565:108-122.
27. Morton CA, Dominicus R, Radny P, et al. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy. British Journal of Dermatology. 2018;179(2):309-319.
28. Mohammadpour R, Dobrovolskaia MA, Cheney DL, et al. Subchronic and chronic toxicity evaluation of inorganic nanoparticles for Delivery Applications. Advanced Drug Delivery Reviews. 2019;144:112-132.
29. Tang W, Fan W, Lau J, et al. Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics. Chemical Society Reviews. 2019;48(11):2967-3014.
30. McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (SBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of SBCC. British Journal of Dermatology. 2013;169(3):549-554.
31. Łasińska I, Zielińska A, Mackiewicz J, et al. Basal cell carcinoma: Pathology, current clinical treatment, and potential use of lipid nanoparticles. Cancers. 2022;14(11):2778.
32. Dourmishev LA, Rusinova D, Botev I. Clinical variants, stages, and management of basal cell carcinoma. Indian Dermatology Online Journal. 2013;4(1):12.

KNIŽNÍ NOVINKA

Nina Benáková a kol.

MODERNÍ FARMAKOTERAPIE V DERMATOLOGII
2. doplněné vydání

Druhé doplněné vydání mimořádně úspěšné publikace, která zásadně ovlivnila preskripci léků v české a slovenské dermatologii. Autorský kolektiv složený z uznávaných odborníků se zaměřuje na praktické konkrétní návody k preskripci. Publikace je určena jak pro každodenní použití v praxi, tak pro přípravu ke specializačním zkouškám. Aktuální informace na úrovni roku 2023, včetně biologické a molekulárně cílené léčby.

Maxdorf 2023, 728 str., edice Jessenius, ISBN: 978-80-7345-766-2, Cena: 1 195 Kč, Formát: 160 × 225 mm, brožovaná

Maxdorf, s. r. o., Na Šejdru 247/6a, 142 00 Praha 4, tel.: 241 011 681–9, fax: 241 710 245, www.maxdorf.cz, e-mail: info@maxdorf.cz